异位性皮肤炎药物市场规模、份额、成长分析，按产品类型、药物类别、治疗方法、给药途径、分布和地区划分 - 产业预测，2025-2032 年

预计2023年全球异位性皮肤炎药物市场规模将达到149.1亿美元，将从2024年的162.8亿美元成长到2032年的329.2亿美元，预测期内（2025-2032年）的复合年增长率为9.2%。

截至 2023 年 10 月，市场洞察显示企业越来越需要适应快速变化的消费者偏好和技术进步。资料显示，消费者越来越倾向于永续实践，越来越喜欢重视环境责任的品牌。此外，随着企业利用人工智慧和资料分析的进步来改善客户体验，数位转型仍然是关注的重点。对个人化产品和服务的需求日益增长，凸显了透过资料主导策略了解客户行为的重要性。竞争格局分析表明，那些重视灵活性和对市场趋势的应对力的创新公司将有利于成长，而那些适应较慢的公司可能会面临维持市场占有率的挑战。整体而言，敏捷性和永续性是塑造当前市场的关键主题。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

异位性皮肤炎治疗市场规模（依产品类型）

• 市场概况
• 生技药品
• 其他的

异位性皮肤炎治疗市场规模（依药物类别）

• 市场概况
• 皮质类固醇
• Calcineurin抑制剂
• PDE4 抑制剂
• 生技药品
• 其他的

异位性皮肤炎治疗市场规模（依治疗方法）

• 市场概况
• 光疗
• 定向治疗

异位性皮肤炎治疗市场规模（依给药途径）

• 市场概况
• 局部的
• 肠外
• 口服

异位性皮肤炎治疗市场规模分布

• 市场概况
• 医院药房
• 零售药局
• 其他药局

异位性皮肤炎治疗市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Astellas Pharma Inc.（Japan）
• Bayer AG（Germany）
• Allergan plc（Ireland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Sanofi SA（France）
• Incyte Corporation（USA）
• AbbVie Inc.（USA）
• Galderma SA（Switzerland）
• Leo Pharma A/S（Denmark）
• Eli Lilly and Company（USA）
• Amgen Inc.（USA）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Bristol-Myers Squibb Company（USA）
• Almirall, SA（Spain）
• Sun Pharmaceutical Industries Ltd.（India）

结论和建议

Global Atopic Dermatitis Drugs Market size was valued at USD 14.91 billion in 2023 and is poised to grow from USD 16.28 billion in 2024 to USD 32.92 billion by 2032, growing at a CAGR of 9.2% during the forecast period (2025-2032).

As of October 2023, market insights indicate a growing need for businesses to adapt to rapidly evolving consumer preferences and technological advancements. The data reveals a significant shift towards sustainable practices, with consumers increasingly favoring brands that prioritize environmental responsibility. Additionally, digital transformation remains a critical focus, as companies leverage advancements in artificial intelligence and data analytics to enhance customer experiences. The demand for personalized products and services is rising, emphasizing the importance of understanding customer behavior through data-driven strategies. Competitive landscape analysis suggests that innovative companies that prioritize flexibility and responsiveness to market trends are well-positioned for growth, while those lagging in adaptation may face challenges in retaining market share. Overall, agility and sustainability are key themes shaping the current marketplace.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atopic Dermatitis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Atopic Dermatitis Drugs Market Segments Analysis

Global Atopic Dermatitis Drugs Market is segmented by Product Type, Drug Class, Therapy, Route of Administration, Distribution and region. Based on Product Type, the market is segmented into Biologics and Others. Based on Drug Class, the market is segmented into Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics and Others. Based on Therapy, the market is segmented into Photo Therapy and Directed Therapy. Based on Route of Administration, the market is segmented into Topical, Parenteral and Oral. Based on Distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Other Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Atopic Dermatitis Drugs Market

The global market for atopic dermatitis drugs is anticipated to expand significantly due to the increasing incidence of this condition, which is attributed to factors such as environmental changes, urbanization, and genetic factors. As awareness of atopic dermatitis grows and its prevalence rises, particularly among children and young adults, the demand for effective treatments is expected to surge. This shift in demographics and the associated rise in cases highlight the urgent need for innovative drugs and therapies, driving market growth and development in the global healthcare landscape devoted to managing atopic dermatitis.

Restraints in the Global Atopic Dermatitis Drugs Market

The Global Atopic Dermatitis Drugs market faces significant challenges due to the side effects associated with certain treatments, raising concerns about long-term patient safety. Specifically, systemic immunosuppressants used for managing atopic dermatitis can lead to adverse effects, including increased susceptibility to infections and liver toxicity. These complications not only diminish patients' quality of life but also hinder the overall growth potential of the atopic dermatitis drugs market. As patients and healthcare providers weigh the risks versus benefits of these medications, the concerns surrounding safety could limit their widespread adoption and dampen market expansion.

Market Trends of the Global Atopic Dermatitis Drugs Market

The Global Atopic Dermatitis Drugs market is poised for significant growth through 2031, driven largely by the increasing adoption of JAK inhibitors such as upadacitinib and abrocitinib. These innovative therapies offer rapid symptom relief and effectively address the unmet medical needs of patients suffering from atopic dermatitis, positioning themselves as essential treatment options. Pharmaceutical companies are anticipated to prioritize the development and marketing of JAK inhibitors, capitalizing on their efficacy and favorable safety profiles. As awareness of these therapies expands, they are expected to dominate the treatment landscape, shaping the future of the atopic dermatitis market and enhancing patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Atopic Dermatitis Drugs Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Photo Therapy
• Directed Therapy

Global Atopic Dermatitis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Topical
• Parenteral
• Oral

Global Atopic Dermatitis Drugs Market Size by Distribution & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies

Global Atopic Dermatitis Drugs Market Size & CAGR (2025-2032)

• North America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • US
  • Canada
• Europe (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations